Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures

Launched by TNF PHARMACEUTICALS, INC. · Apr 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called Isomyosamine to see if it can help older adults recover better after hip or thigh bone fractures. The focus is on people who are experiencing muscle weakness or frailty, which often happens as we age. Isomyosamine is taken as a pill and works by reducing inflammation, which can help improve muscle strength and mobility. The goal of the trial is to find out if this medication can make a difference in how well older patients heal after their injuries.

To be eligible for this study, participants need to be between 60 and 85 years old and have had a specific type of hip fracture due to a fall. They should also have a history of muscle weakness or frailty. If someone joins the trial, they will be closely monitored to see how well the medication works and if it is safe for them. It’s important to know that the study is not yet recruiting participants, but it aims to help improve recovery for many older adults in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 60 to 85 years of age
• • 2. Non-complex, non-comminuted fracture of the femoral head, femoral neck, or acetabulum due to an accidental (non-neurologic or cardiovascular) fall
• • 3. Concomitant medication limited to treatment for chronic conditions
• • 4. The ability to give informed consent and comply with study procedures
• • 5. Body weight ≥35 kg
• • 6. Adequate dietary intake
• • 7. Potential subjects' intention to avoid reproductive activity will be confirmed
• And one or more of the following criteria:
• • 8. Previous history frailty or sarcopenia diagnosis using standardized tests;
• • 9. Positive assessment for frailty or sarcopenia using standardized tests or as per clinician's judgement;
• • 10. Previous positive assessment for elevated biomarkers of inflammation (serum IL-6 level\> LOQ, TNFR1 level \> LOQ, and/or TNF-alpha level \> LOQ)
• Exclusion Criteria:
• • 1. Receiving immunotherapy for cancer or solid organ transplantation
• • 2. Complex or comminuted fracture or fracture of multiple long bones
• • 3. Regular treatment for chronic disease including chronic renal failure, chronic heart failure (CHF) cerebrovascular disease including stroke, rheumatoid arthritis, or polymyalgia rheumatica
• • 4. Chronic kidney disease (estimated glomerular filtration rate \[eGFR\] \<60 mL/min)
• • 5. Newly (\< 2 weeks) diagnosed COVID-19
• • 6. Inability or unwillingness to give written informed consent
• • 7. History of upper/lower respiratory tract infection, requiring systemic steroids, antibiotics, and or emergency room (ER) visit or urgent care within 6 weeks of screening visit
• • 8. History of adverse reaction or allergy to TNF inhibitor
• • 9. History of neurological, hepatic, renal, diabetic mellitus, thyroid disorder, psychiatric, addiction or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns per investigator discretion
• • 10. Currently under treatment by an anti-TNFα drug, such as adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and biosimilars
• • 11. Currently under treatment by an anti-diabetic medication, including glucagon-like peptide-1 (GLP-1) drugs such as semaglutide, or any of metformin, jenuvia, or insulin
• • 12. Unwillingness or inability to comply with study procedures, including smoking cessation
• • 13. History of epilepsy or seizure propensity, ataxia, abnormal EEG findings, abnormal brain magnetic resonance image, or other co-morbid neurological conditions
• • 14. Positive TB test
• • 15. Patients who are pregnant or breastfeeding